Cosentyx is a medication manufactured by Novartis Pharmaceuticals Corporation and aligned to the J Code: J3247. Cosentyx is administered via the Intravenous route of administration.
J3247: Permanent J-code for the IV formulation of COSENTYX Effective J, for all sites of care. If COSENTYX is administered on or after J, the permanent J-code replaces the miscellaneous J-code J3590.
Cosentyx 125mg/5ml IV Dose and Quantity: Duration of therapy: J-Code: Frequency of administration : ICD10:
CODE. DESCRIPTION. J3590. Unclassified biologic (Cosentyx IV). AVAILABLE McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of
J Code (medical billing code): J3247 (1 mg, intravenous). Medically reviewed Use the COSENTYX UnoReady pen within 5 minutes of removing the cap. Step 5.
□ Secukinumab (Cosentyx Sensoready). □ Secukinumab (Cosentyx UnoReady NDC/HCPCS (J Code). Strength. Dosage Form. Quantity. Directions for Use.
If COSENTYX is administered on or after J, the permanent J-code replaces the miscellaneous J-code J3590. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.
HCPCS Level II codes are used to identify drugs, supplies, medical procedures, and other services. As As of J, a permanent J-code is available for the IV formulation of COSENTYX (secukinumab).
J3247: Permanent J-code for the intravenous (IV) formulation of COSENTYX (secukinumab) . Effective J, for all sites of care If COSENTYX is administered on or after J, the permanent J-code replaces the miscellaneous J-code, J3590.
R.